Compliance set to be big challenge for EU industry
This article was originally published in SRA
Life sciences companies in Europe will find regulatory compliance "a major challenge" over the next few years as the UK Bribery Act, and other measures, comes in to force, shows a survey from Cegedim Relationship Management1. Firms will have to revaluate how sales reps – "the face of industry" – are used and get to grips with operational compliance.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.